Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias.

Autor: Pietka G; Division of Molecular Pathology, Institute of Cancer Research, London, UK.; Department of Translational Research, Royal Marsden Hospital NHS Trust, London, UK., De Lord C; Department of Haematology, St Helier Hospital, London, UK.; Department of Haematology, Royal Marsden Hospital NHS Trust, London, UK., Matthias G; Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK., Cheung B; Department of Haematology, Croydon University Hospital, London, UK., Atwal S; Department of Haematology, Kingston Hospital NHS Foundation Trust, London, UK., Furtado M; Department of Haematology, Royal Cornwall Hospitals NHS Foundation Trust, Cornwall, Truro, UK., Cullis J; Department of Haematology, Salisbury NHS Foundation Trust, Salisbury, UK., Grey-Davies L; Department of Haematology, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK., Narayanan S; Department of Haematology, University Hospital Southampton, Southampton, UK., McGregor A; Department of Haematology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK., Kilner M; Department of Haematology, Northumbria Healthcare NHS Foundation Trust, Tyneside, UK., Bosworth J; Department of Haematology, St Helier Hospital, London, UK.; Department of Haematology, Royal Marsden Hospital NHS Trust, London, UK., McMullin MF; Department of Haematology, Queen's University, Belfast, UK., Coats T; Department of Haematology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., Parcharidou A; Department of Haematology, Northwick Park Hospital, London, UK., Cavenagh J; Department of Haematology, St Bartholomew's Hospital, London, UK., Byrne J; Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Iyengar S; Department of Haematology, Royal Marsden Hospital NHS Trust, London, UK., Mohammed K; Department of Statistics, Royal Marsden Hospital NHS Trust, London, UK., Cross N; Faculty of Medicine, University of Southampton, Southampton, UK.; Wessex Genomics Laboratory Service, Salisbury NHS Foundation Trust, Salisbury, UK., Hubank M; Department of Translational Research, Royal Marsden Hospital Sutton, London, UK.; Division of Molecular Pathology, Clinical Genomics (Research), Institute of Cancer Research, London, UK., Ribeiro S; Department of Molecular Pathology, Royal Marsden Hospital Sutton, London, UK., Khorashad J; Department of Molecular Pathology, Royal Marsden Hospital Sutton, London, UK., Wren D; Department of Molecular Pathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK., O'Connor S; Department of Histopathology, Royal Marsden NHS Foundation Trust, London, UK., Taussig D; Division of Molecular Pathology, Institute of Cancer Research, London, UK.; Department of Haematology, Royal Marsden Hospital NHS Trust, London, UK.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Apr; Vol. 204 (4), pp. 1325-1334. Date of Electronic Publication: 2024 Mar 11.

Antinuclear antibody-associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus.

Autor: Granel J; Paediatric Clinical Immunology, Pellegrin Hospital, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France., Fernandes H; Paediatric Clinical Immunology, Pellegrin Hospital, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France., Bader-Meunier B; Paediatric Haematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France., Guth A; Paediatric Department, Pontarlier Hospital, Pontarlier, France., Richer O; Paediatric Clinical Immunology, Pellegrin Hospital, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France., Pillet P; Paediatric Clinical Immunology, Pellegrin Hospital, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France., Leverger G; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France.; Paediatric Oncology Immunology Haematology Unit, Armand-Trousseau University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Ducassou S; Paediatric Clinical Immunology, Pellegrin Hospital, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France., Fahd M; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France.; Paediatric Haematology and Immunology Unit, Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Pasquet M; Paediatric Oncology Immunology Haematology Unit, Children's University Hospital, Toulouse, France., Garnier N; Institute of Paediatric Haematology and Oncology, Hospices Civils de Lyon, Lyon, France., Barlogis V; Department of Paediatric Haematology, La Timone Hospital, Marseille University Hospital, Marseille, France., Guitton C; Department of Paediatrics, Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France., Jeziorski E; Paediatric Oncology Haematology Unit, Arnaud de Villeneuve University Hospital, Montpellier, France., Thomas C; Paediatric Haematology Unit, Nantes University Hospital, Nantes, France., Bayart S; Paediatric Haematology Unit, Rennes University Hospital, Rennes, France., Cheikh N; Department of Paediatric Haematology-Oncology, Besançon University Hospital, Besançon, France., Paillard C; Department of Paediatric Haematology and Oncology, Hautepierre University Hospital, Strasbourg, France., Abou Chahla W; Department of Paediatric Haematology, Jeanne de Flandre Hospital, Lille University Hospital, Lille, France., Chastagner P; Department of Paediatric Haematology and Oncology, Children's University Hospital, Nancy, France., Neven B; Paediatric Haematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France., Millot F; Department of Paediatric Haematology, Poitiers University Hospital, Poitiers, France., Lejeune J; Department of Paediatric Haematology-Oncology, Clocheville Hospital, Tours University Hospital, Tours, France., Li-Thiao Te V; Department of Paediatric Haematology/Oncology, Amiens University Hospital, Amiens, France., Armari-Alla C; Paediatric Haematology-Oncology Department, Grenoble University Hospital, Grenoble, France., Briandet C; Department of Paediatrics, Dijon University Hospital, Dijon, France., Carausu L; Department of Paediatric Hematology, CHU de Brest, Brest, France., Deparis M; Paediatric Oncology- Haematology Unit Department, Caen University Hospital, Caen, France., Piguet C; Paediatric Oncology Hematology Unit, Limoges University Hospital, Limoges, France., Benadiba J; Department of Haematology-Oncology Paediatrics, Nice University Hospital, Nice, France., Marie-Cardine A; Department of Paediatric Haematology and Oncology, Rouen University Hospital, Rouen, France., Stephan JL; University Hospital of Saint Etienne, North Hospital, Department of Paediatric Oncology, Saint Etienne, France., Pellier I; Paediatric Unit, Angers University Hospital, Angers, France., Pluchart C; Paediatric Haematology-Oncology Unit, Institut Jean Godinot, Reims University Hospital, Reims, France., Doré E; Paediatric Unit, Clermont-Ferrand University Hospital, Clermont-Ferrand, France., Michaux K; Paediatric Unit, Martinique University Hospital, Fort-de-France, France., Héritier S; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France.; Paediatric Oncology Immunology Haematology Unit, Armand-Trousseau University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Leblanc T; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France.; Paediatric Haematology and Immunology Unit, Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Aladjidi N; Paediatric Clinical Immunology, Pellegrin Hospital, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France.

Publikováno v: Blood [Blood] 2024 Apr 18; Vol. 143 (16), pp. 1576-1585.

Granulocyte transfusion supportive care for prolonged cytopenias post CD19 CAR T cell therapy.

Autor: Perera N; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia.; Faculty of Medicine, The University of Queensland, St Lucia, Australia., Baidya S; Australian Red Cross Lifeblood, Melbourne, Australia., Weber N; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia., Mudie K; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia., Butler J; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia., Curley C; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia.; Faculty of Medicine, The University of Queensland, St Lucia, Australia., Henden A; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia.; Faculty of Medicine, The University of Queensland, St Lucia, Australia.; Translational Cancer Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Australia., Hunt S; Australian Red Cross Lifeblood, Melbourne, Australia., Subramoniapillai E; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia., Tey SK; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia.; Translational Cancer Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Australia., Kennedy GA; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia., Scott AP; Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Herston, Australia.; Faculty of Medicine, The University of Queensland, St Lucia, Australia.

Publikováno v: Transfusion [Transfusion] 2024 Apr; Vol. 64 (4), pp. 762-765.

Clinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS-IT).

Autor: O'Neill C; Jane Anne Nohl Division of Hematology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., Nwachukwu N; Jane Anne Nohl Division of Hematology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., Vergara-Lluri M; Department of Pathology, Hematopathology Section, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., Hagiya A; Department of Pathology, Hematopathology Section, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., O'Connell CL; Jane Anne Nohl Division of Hematology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.

Publikováno v: European journal of haematology [Eur J Haematol] 2024 Apr; Vol. 112 (4), pp. 594-600. Date of Electronic Publication: 2023 Dec 13.

Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.

Autor: Dima D; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio, USA., Rashid A; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Davis JA; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Department of Hematology-Oncology, Medical College of South Carolina, Charleston, South Carolina, USA., Shune L; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Abdallah AO; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Li H; Department of Biostatistics and Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA., DeJarnette S; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Khouri J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio, USA., Williams L; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio, USA., Hashmi H; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Department of Hematology-Oncology, Medical College of South Carolina, Charleston, South Carolina, USA., Raza S; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA., McGuirk J; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Anwer F; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio, USA., Ahmed N; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, Kansas, USA.; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Apr; Vol. 204 (4), pp. 1293-1299. Date of Electronic Publication: 2024 Jan 23.